How Lipitor Works on Its Main Target
Lipitor (atorvastatin) primarily disrupts HMG-CoA reductase, a key enzyme in the mevalonate pathway. It competitively inhibits this enzyme by mimicking its substrate, HMG-CoA, which blocks the conversion of HMG-CoA to mevalonate. This reduces cholesterol synthesis in the liver, prompting increased LDL receptor expression to clear LDL from blood.[1]
What Happens Downstream from HMG-CoA Reductase Inhibition
Beyond the primary target, inhibition lowers levels of isoprenoids like farnesyl pyrophosphate and geranylgeranyl pyrophosphate. These molecules are needed for prenylation—a lipid modification—of small GTPases such as Rho, Rac, Ras, and Cdc42. Without prenylation, these proteins fail to anchor to cell membranes, disrupting their signaling roles in cell growth, inflammation, and vascular function.[2][3]
Does Lipitor Affect Other Proteins?
Lipitor has minor effects on additional proteins, including:
- Reduction in PCSK9 expression, aiding LDL receptor recycling.
- Decreased levels of proinflammatory cytokines via NF-κB pathway modulation.
These are pleiotropic (off-target) effects, not primary disruptions, and vary by dose and patient.[4]
Why Focus on HMG-CoA Reductase for Drug Design?
This enzyme's specificity makes statins like Lipitor effective for hypercholesterolemia. Patents on atorvastatin targeted formulations around this mechanism; U.S. Patent 5,273,995 expired in 2011, enabling generics.[5] (Source: DrugPatentWatch.com)
[1] Istvan ES, Deisenhofer J. Science. 2001;292(5520):1160-1164. Link
[2] Liao JK, Laufs U. J Clin Invest. 2005;115(11):2857-2867. Link
[3] Takemoto M, Liao JK. Arterioscler Thromb Vasc Biol. 2001;21(12):2051-2059. Link
[4] Davignon J. Atherosclerosis. 2004;175(1):1-12. Link
[5] DrugPatentWatch.com. Atorvastatin patents. Link